BlackRock, Inc. 13D and 13G filings for Lifecore Biomedical, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-17 6:41 pm Sale | 2025-09-30 | 13G | Lifecore Biomedical, Inc. LFCR | BlackRock Inc. BLK | 1,834,319 4.900% | -34,184 (-1.83%) | Filing |
| 2025-07-17 8:12 pm Purchase | 2025-06-30 | 13G | Lifecore Biomedical, Inc. LFCR | BlackRock Inc. BLK | 1,868,503 5.000% | 1,336,460 (+251.19%) | Filing |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | Lifecore Biomedical, Inc. LFCR | BlackRock Inc. BLK | 532,043 1.800% | -1,316,110 (-71.21%) | Filing |
| 2023-02-01 4:54 pm Sale | 2022-12-31 | 13G | Lifecore Biomedical, Inc. LFCR | BlackRock Inc. BLK | 1,848,153 6.200% | -98,305 (-5.05%) | Filing |
| 2022-02-01 5:08 pm Sale | 2021-12-31 | 13G | Lifecore Biomedical, Inc. LFCR | BlackRock Inc. BLK | 1,946,458 6.600% | -144,572 (-6.91%) | Filing |
| 2021-01-29 5:23 pm Purchase | 2020-12-31 | 13G | Lifecore Biomedical, Inc. LFCR | BlackRock Inc. BLK | 2,091,030 7.200% | 79,319 (+3.94%) | Filing |